Authors
Latest:
Game Changer: Transformative Decentralized Clinical Trials Emerge in Latin AmericaRegional factors impact direct-to-patient modalities and bring the benefits of DCTs to life.
Latest:
Identifying Integrated Digital Platforms Designed for a Decentralized FutureCOVID-19 forces sponsors to take new approach for assessing trial support models.
Latest:
Harnessing the Power of Scientific SurveillanceStatistical methods used via this technique in centralized monitoring.
Latest:
Five Areas That Will Define the Future of Clinical TrialsFollowing COVID-19, companies are focused on solutions offering the latest technology and most value to patients.
Latest:
Understanding Study Coordinator Work QualitySurvey from the Site Council gathered insights from its members on the quality of site coordinator work.
Latest:
Four Hundred Scientists Share Secrets to Maximizing R&D DataMaximizing the impact of data is only possible when strong fundamental data management capabilities are in place.
Latest:
Beyond Regulatory Intelligence: How an FSP PV Partner Helps Ensure Global ComplianceSupport from these partners can aid drug and medical device developers in keeping up with the evolving regulatory landscape.
Latest:
Survey Results: GCP Quality and Risks in Decentralized Clinical TrialsIdentifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.
Latest:
Recruiting Trial Workers Amidst Growing ComplexityEconomic challenges combined with increased responsibility for clinical trial workers has shifted talent recruitment.
Latest:
A View of Electronic Signature in Clinical Trial Agreements in MalaysiaA focus on the position of law for e-signatures, their benefits, and the role of Clinical Research Malaysia in educating the industry on the practicality of e-signature.
Latest:
COVID-19 and Its Impact on the Future of Clinical Trial ExecutionFindings from a Tufts study examining the effects of COVID-19 on clinical trials.
Latest:
Upping the Ante for Predicting the Success of Alzheimer Disease TreatmentsThe use of modeling and biosimulation can help predict potential outcomes and improve confidence in therapeutic candidates for Alzheimer disease.
Latest:
How AI is Changing Early Drug DevelopmentThough artificial intelligence has yet to achieve its full potential, meaningful strides are still being made across the drug discovery funnel.
Latest:
Diversity by Design: Combining Strategic Protocol Planning with Accurate Real-world DataLeveraging a “diversity by design” approach can build patient narratives and optimize protocols from the onset.
Latest:
The African Medicines Agency: Impacts on the Continent’s Clinical Trials RegulationHarmonization could turn the continent into an established site for clinical research and laboratories.
Latest:
Rare Disease Clinical Trials: Strategies Learned from Duchenne Muscular DystrophyApproaches sponsors, CROs, and investigators can take from the DMD experience.
Latest:
Strategies for Building Greater DE&I in Rare Disease TrialsOutlining new approaches and resources to help ignite progress in this area.
Latest:
Considerations for Combination Product Registrations in the US and the EUIn this eBook learn about varying categorizations and how they impact combination product registrations in the US and EU markets.
Latest:
Collecting Data from Multiple Study SitesCase study shows how one CRO ensured high-quality, consistent data in a difficult therapeutic area.
Latest:
How CROs are Uniquely Positioned to Drive Adoption of the TMF Exchange MechanismWork across varying therapeutic areas and new technology among reasons why CROs are qualified to advance model.
Latest:
The Key to Clinical Trial Success: Patient TokenizationWednesday, October 12, 2022 11am PDT | 2pm EDT | 7pm BST | 8pm CEST Real-world-data (RWD) leads to real-world results. Learn how RWD & patient tokenization are streamlining clinical trials and ensuring successful results.
Latest:
Five Critical Qualities for Identifying a Partner to Globally Scale Ophthalmology Clinical TrialsAmplifying the size and diversity of participant pools in clinical trials enhances statistical power and increases the generalizability of study findings.
Latest:
Seven Ways Clinical Trials Will Look Different by the End of 2021Changes predicted to change the face of clinical research in 2021.
Latest:
AI/ML Approaches to Assisted Medical Writing—Part 2Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.
Latest:
Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease TrialsIntegrated approaches can help enhance recruitment plans.
Latest:
eSource Interoperability Between EHR and EDCEvidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Latest:
Ten Considerations for Sensor Selection in Clinical TrialsThe careful selection of sensor technology prioritized in clinical trials, considering regulatory compliance, data security, device characteristics, and the specific needs of the trials for successful and confident implementation.
Latest:
From Physician to Pharma: Gynecologic Oncologist Enters Clinical Trials SpaceIn an interview with Applied Clinical Trials' sister publication, Pharmaceutical Executive, Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically clinical trials.
Latest:
Establishing a Basis for Secondary Use Standards for Clinical TrialsStudy seeks to understand how different forms of data meet the needs of researchers.
